These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 29987326

  • 1. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, Bekiari E, Matthews DR, Tsapas A.
    Ann Intern Med; 2018 Aug 07; 169(3):165-174. PubMed ID: 29987326
    [Abstract] [Full Text] [Related]

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
    Martin, Zhou Y, Takagi T, Tian YS.
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct 09; 394(10):2091-2101. PubMed ID: 34319421
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.
    Martin, Zhou Y, Takagi T, Tian YS.
    Int J Clin Pharm; 2022 Jun 09; 44(3):587-598. PubMed ID: 35476308
    [Abstract] [Full Text] [Related]

  • 12. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.
    Retnakaran R, Ye C, Emery A, Kramer CK, Zinman B.
    Nat Commun; 2022 Oct 16; 13(1):6109. PubMed ID: 36244997
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL, Kerr L, Malone JK, Tan MH.
    Clin Ther; 2007 Oct 16; 29 Spec No():1254-70. PubMed ID: 18046926
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.
    Freemantle N, Chou E, Frois C, Zhuo D, Lehmacher W, Vlajnic A, Wang H, Chung HW, Zhang Q, Wu E, Gerrits C.
    BMJ Open; 2016 Feb 15; 6(2):e009421. PubMed ID: 26880669
    [Abstract] [Full Text] [Related]

  • 16. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
    Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ.
    JAMA; 2018 Jul 03; 320(1):53-62. PubMed ID: 29936529
    [Abstract] [Full Text] [Related]

  • 17. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
    Zhang T, Ji L, Gao Y, Zhang P, Zhu D, Li X, Ji J, Zhao F, Zhang H, Guo X.
    Diabetes Technol Ther; 2017 Nov 03; 19(11):675-684. PubMed ID: 29090977
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P, Sugimoto D, Vlajnic A, Kilo C.
    J Diabetes Complications; 2015 Nov 03; 29(8):1266-71. PubMed ID: 26281972
    [Abstract] [Full Text] [Related]

  • 19. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S, Facchinetti A, Bonora BM, Mariano V, Boscari F, Cipponeri E, Maran A, Avogaro A, Fadini GP, Bruttomesso D.
    Nutr Metab Cardiovasc Dis; 2016 Dec 03; 26(12):1112-1119. PubMed ID: 27618501
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T, Lin M, Li W, Fan X, Du T, Zhao Y, Zhang X.
    Adv Ther; 2016 Feb 03; 33(2):178-85. PubMed ID: 26809253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.